|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Ambrilia Biopharma Inc., of Montreal, presented preclinical data on its series of HIV integrase inhibitors, showing their potential distinct mechanism of action, which may lead to a different resistance profile than other integrase inhibitors. The abstract was presented during a poster session at the XVI International HIV Drug Resistance Workshop in Barbados. The pyrazolopyridine integrase inhibitors demonstrated potent inhibition of integrase strand transfer activity but did not exhibit significant inhibition of integrase 3'-processing activity, Ambrilia said.
o Evotec AG, of Hamburg, Germany, said it enhanced its Fragment-Based Drug Discovery business through ...